MorphoSys Announces First Scientific Publication on Novel Antibody Platform Ylanthia
News May 13, 2013
MorphoSys AG has announced that a first scientific publication on the Company's novel, proprietary antibody platform Ylanthia was published in the current issue of "mAbs".
The article titled "A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties" describes for the first time the detailed design, generation and testing of the Ylanthia library.
Ylanthia became commercially available for existing and new partners in 2012 and is currently used in two commercial agreements.
"Ylanthia sets new standards for therapeutic antibody generation. Its unique and innovative design translates into unprecedented structural diversity which is expected to result in antibodies against previously inaccessible target molecules and covering a unique epitope space. Furthermore, our scientists introduced an entirely new concept to improve biophysical characteristics that are relevant for antibody selection, manufacturing and administration, finally leading to better drugs," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
To confirm the functionality and quality of the Ylanthia antibody library, phage selections against several antigens were performed.
Subsequent antibody characterization revealed broad diversity and significantly improved biophysical properties including a very low aggregation tendency, increased thermodynamic stability and favorable solubility of Ylanthia antibodies.
Ylanthia comprises more than 100 billion distinct, fully human antibodies, which makes it the industry's largest known antibody Fab library. It uses 36 fixed, naturally-occurring heavy and light chain framework combinations, which translates into very broad structural diversity.
Ylanthia's antibody frameworks were pre-selected for favorable expression levels, stability and aggregation behavior.
A shift towards higher stability and stress tolerance will increase shelf life and serum stability of resulting antibody products, making them more cost-effective to produce.
A higher solubility in turn opens up the path for more convenient ways of administration, to the benefit of patients.
When needed, antibodies from the Ylanthia library are optimized using MorphoSys's proprietary Slonomics technology.
Slonomics enables optimization of Ylanthia antibodies with unprecedented speed and flexibility.
Innate Reaction of Hematopoietic Stem Cells to Severe InfectionsNews
Researchers at the University of Zurich have shown for the first time that hematopoietic stem cells detect infectious agents themselves and begin to divide, without signals from growth factors.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
New Way Found to Boost Immunity in Fighting Cancer and InfectionsNews
Researchers have identified a key new mechanism that regulates the ability of T-cells of the immune system to react against foreign antigens and cancer.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Transgenic Animals - Micromanipulation Techniques
Apr 10 - Apr 11, 2018
EMBO Practical Course: Extracellular Vesicles: From Biology to Biomedical Applications
Apr 09 - Apr 13, 2018
EMBO | EMBL Symposium: Tissue Self-Organisation: Challenging the Systems
Mar 11 - Mar 14, 2018
EMBL Course: Brillouin Microscopy: Emerging Tool for Probing Mechanical Properties of Living Cells
Jan 17 - Jan 19, 2018